VE303 phase 2 trial stool metagenomes in CDI patients
CONSORTIUM VE303 phase 2 study stool metagenomes
500 stool samples from participants across US and Canada sites in a randomized, double-blind, placebo-controlled dose-ranging trial of VE303, a live biotherapeutic consortium, for prevention of recurrent C. difficile infection. machine-written summary
500 samples · 500 runs · US, CA · Age unknown · 2024 · 0.58 Gbp / sample
Defined bacterial consortium / live biotherapeutic productdesignrandomized_controlled_trial · populationgi_infection_or_diarrhoea · VE303, defined 8-strain bacterial consortium, oral, 14 days
“randomly assigned to high-dose VE303” — abstract:37060545 (study level; per-sample arms are in the intervention column below)
Samples at a glance
2 countries
Age
unknown500
Condition
gi_infection_or_diarrhoea500
Country
US296
CA204
Body site
primary500
Collected 2019–2021
Sequencing depth per sample · this project all projects
Sampling design and relatedness
longitudinal
78 of 78 people sampled more than once (500 samples; median 7, up to 9 per person) · follow-up median 6 mo (max 6 mo) · median interval between samples 13 d(time from collection dates).
Schedule stated by the source: “Repeated stool sampling per subject over trial course (median 7, max 9 samples/subject across 78 subjects)”; stated follow-up 56 d.
Each row is one person (36 shown of 78); dots are samples at days since that person's first sample.
Bacteroides 9.3%Klebsiella 8.3%Escherichia 6.2%Prevotella 3.6%Enterocloster 3.5%Mediterraneibacter 3.4%Blautia_A 3.2%Phocaeicola 2.9%Akkermansia 2.6%Parabacteroides 2.5%Blautia 2.3%Veillonella 2.3%not assigned to a genus 12.4%other genera 37.7%
Genera, mean relative abundance over 422 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. 2023PMID 37060545PMC10105904own_data
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection. 2025PMID 39747680own_data
Details
Archive description
Stool metagenomes from the patients enrolled in the VE303 phase 2 CONSORTIUM Study. The goals of these sequences are to characterize VE303 strain colonization dynamics and microbiota community composition in CDI patients.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.85. Assay shotgun_dna.
hostrun.host_tax_id · “9606”
hoststudy.description · “Stool metagenomes from the patients”
body sitestudy.title · “phase 2 study stool metagenomes”
Evidence examples (one per field × route)
sample
field
value
route
conf.
source
quote
SAMN41746833
collection_date
2019-08-15
R1
0.90
biosample.attribute:collection_date
2019-08-15
SAMN41746833
country
US
R1
0.90
sample.attr.geo_loc_name
USA: AR,Jonesboro
SAMN41746833
health_condition
gi_infection_or_diarrhoea
R1
0.70
sample.name_rule:experiment_title
Illumina HiSeq 4000 sequencing: Stool metagenome from Study VE303-002
SAMN41746833
health_condition_detail
Illumina HiSeq 4000 sequencing: Stool metagenome from Study VE303-002
R1
0.70
sample.name_rule:experiment_title
Illumina HiSeq 4000 sequencing: Stool metagenome from Study VE303-002
SAMN41746833
location_locality
Jonesboro
R1
0.85
biosample.attribute:geo_loc_name
USA: AR,Jonesboro
SAMN41746833
location_region
Arkansas
R1
0.75
biosample.attribute:geo_loc_name
USA: AR,Jonesboro
SAMN41746833
subject_id
100601
R1
0.85
sample.attr.subject_number
100601
Sequencing
500 runs over 500 samples · mean 0.63 Gbp per run (median 0.58 Gbp, total 315.00 Gbp; 500 runs with a base count) · layout SINGLE 500 · platform ILLUMINA 500 · models Illumina HiSeq 4000 (500) · 84% of runs with a Sandpiper profile · first public 2024-10-27